Log in to save to my catalogue

Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French rea...

Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French rea...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_318647e3ed8f4622944ee433cb371756

Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study

Publication information

Publisher

London: BioMed Central Ltd

More information

Scope and Contents

Contents

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord. Nusinersen has been covered by public healthcare in France since May 2017. The aim of this article is to report results after 1 year of treatment with intrathecal nusinersen in children with SMA...

Alternative Titles

Full title

Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_318647e3ed8f4622944ee433cb371756

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_318647e3ed8f4622944ee433cb371756

Other Identifiers

ISSN

1750-1172

E-ISSN

1750-1172

DOI

10.1186/s13023-020-01414-8

How to access this item